Tedaviye dirençli hızlı döngülü ikiuçlu bozukluğu olan bir ergende olanzapin monoterapisiyle başarılı mizaç stabilizasyonu Olanzapine seems to be an effective choice during both acute phase and maintenance treatment of bipolar disorder in adolescents. Also, improvement in manic symptoms appears in the early days of treatment.
INTRODUCTION
The course of bipolar disorder in adolescents appears to be more chronic and refractory to treatment than adult onset (1) . A pattern of illness of very rapid, brief, recurrent episodes lasting hours to a few days is common (2) . Here we report a 16 years-old adolescent with rapid cycling bipolar disorder who responded well to olanzapine monotherapy both at the acute manic phase and during the maintenance treatment.
CASE
A 16-year-old male adolescent was referred to our inpatient clinic with the symptoms of a decrease in sleep, physical restlessness, irritability, increase in self-esteem, going away from home, spending the night at nightclubs and using illicit drugs. These symptoms were present and and observed by the parents for ten days. Parents reported that their son was diagnosed with bipolar disorder in a child and adolescent psychiatry clinic four years ago and used various drugs without any treatment response. The case was depressed and withdrawn for 13-15 days and after then he was changing quickly to a different mood and becoming restless, spending the night out with friends and using illicit drugs, going far away from home, getting lost and every time found by the help of police. After 12-13 days, his energy level was decreasing and again he was turning quickly to depressive-withdrawn phase and staying all day at home doing nothing. Between these two opposite mood swings, the parents described the patient's mood as normal only for one or two days.
He was using valproate 1000 mg/day and aripiprazole 10 mg/day for the last three years, but there was no marked decrease in the frequency or severity of his mood episodes. Risperidone was tried before this regimen but had to be stopped because of dystonia. Olanzapine 10 mg/ day was started and increased to 15 mg/day in our inpatient unit. Approximately in two weeks there was a marked decrease in his manic symptoms and his mood was euthymic. His YMRS (Young Mania Rating Scale) points were; 48 points on admission day, 31 points at the end of first week and 4 points at the end of second week.
He was discharged from the inpatient unit on olanzapine 15 mg/day treatment at the 15th day of his admission. The parents were told to make a life chart for mood changes to characterize the course of illness and patterns of episodes.
During the follow-up for four months he was stable, he had no major mood episodes except two times of hypomania symptoms lasting two days, and once mild depressive symptoms lasting two days not filling the full criteria for hypomania or depression. Olanzapine treatment was well tolerated by the patient except some sedation and non-significant weight gain. He gained 2 kilograms during 4 months' follow-up. His monthly metabolic parameters were between normal ranges without a marked increase.
DISCUSSION
Bipolar disorder in both children and adolescents has high rates of rapid cycling, and low rates of inter-episode recovery (10) . Our case had a rapid cycling bipolar disorder with nearly no inter-episode recovery that is compatible with the literature.
Open-label trials and retrospective chart reviews support the effectiveness of olanzapine for pediatric bipolar disorder. In open-label studies with olanzapine, the average response rate was found as 51% (4) and in a double-blinded study (11) olanzapine was found significantly superior to placebo with a response rate of 49%. Chang and Ketter reported three acutely manic bipolar youths whose symptoms dramatically improved within 3-5 days with olanzapine augmentation to their existing mood stabilizer regimens (12) . An open-label study involving 23 bipolar youths (manic, mixed, or hypomanic) showed that significant improvement was seen at the end of the first week with olanzapine monotherapy (13).
Olanzapine monotherapy was effective both at the acute manic phase and during the maintenance treatment in this case. Also, olanzapine decreased depressive episodes that may be an important finding for pediatric bipolar disorder treatment. Significant improvement was seen from the end of the first week. No manic or depressive episode was seen during four months' follow up. Although one of the most common adverse effects of olanzapine is weight gain, we did not observe significant weight gain during four months follow up.
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